Literature DB >> 14739995

Expression level of Ubc9 protein in rat tissues.

Filip Gołebiowski1, Aneta Szulc, Monika Sakowicz, Andrzej Szutowicz, Tadeusz Pawełczyk.   

Abstract

Ubc9 is a homologue of the E2 ubiquitin conjugating enzyme and participates in the covalent linking of SUMO-1 molecule to the target protein. In this report we describe a simple and efficient method for obtaining pure human recombinant Ubc9 protein. The purified Ubc9 retained its native structure and was fully active in an in vitro sumoylation assay with the promyelocytic leukaemia (PML) peptide as a substrate. In order to better understand the physiology of Ubc9 protein we examined its levels in several rat tissues. Immunoblot analyses performed on tissue extracts revealed quantitative and qualitative differences in the expression pattern of Ubc9. The Ubc9 protein was present at a high level in spleen and lung. Moderate level of Ubc9 was detected in kidney and liver. Low amount of Ubc9 was observed in brain, whereas the 18 kDa band of Ubc9 was barely visible or absent in heart and skeletal muscle. In heart and muscle extracts the Ubc9 antibodies recognized a 38 kDa protein band. This band was not visible in extracts of other rat tissues. A comparison of the relative levels of Ubc9 mRNA and protein indicated that the overall expression level of Ubc9 was the highest in spleen and lung. In spleen, lung, kidney, brain, liver and heart there was a good correlation between the 18 kDa protein and Ubc9 mRNA levels. In skeletal muscle the Ubc9 mRNA level was unproportionally high comparing to the level of the 18 kDa protein. The presented data indicate that in the rat the expression of the Ubc9 protein appears to have some degree of tissue specificity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14739995     DOI: 0350041065

Source DB:  PubMed          Journal:  Acta Biochim Pol        ISSN: 0001-527X            Impact factor:   2.149


  7 in total

1.  MyoD synergizes with the E-protein HEB beta to induce myogenic differentiation.

Authors:  Maura H Parker; Robert L S Perry; Mélanie C Fauteux; Charlotte A Berkes; Michael A Rudnicki
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

2.  Defective sumoylation pathway directs congenital heart disease.

Authors:  Jun Wang; Li Chen; Shu Wen; Huiping Zhu; Wei Yu; Ivan P Moskowitz; Gary M Shaw; Richard H Finnell; Robert J Schwartz
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-05-11

3.  Protein SUMOylation is massively increased in hibernation torpor and is critical for the cytoprotection provided by ischemic preconditioning and hypothermia in SHSY5Y cells.

Authors:  Yang-ja Lee; Shin-ichi Miyake; Hideaki Wakita; David C McMullen; Yoshiaki Azuma; Sungyoung Auh; John M Hallenbeck
Journal:  J Cereb Blood Flow Metab       Date:  2006-09-06       Impact factor: 6.200

Review 4.  Starting and stopping SUMOylation. What regulates the regulator?

Authors:  Felicity Z Watts
Journal:  Chromosoma       Date:  2013-06-28       Impact factor: 4.316

5.  Inhibition of the Ubc9 E2 SUMO-conjugating enzyme-CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain.

Authors:  Liberty François-Moutal; Erik T Dustrude; Yue Wang; Tatiana Brustovetsky; Angie Dorame; Weina Ju; Aubin Moutal; Samantha Perez-Miller; Nickolay Brustovetsky; Vijay Gokhale; May Khanna; Rajesh Khanna
Journal:  Pain       Date:  2018-10       Impact factor: 7.926

Review 6.  Deciphering the SUMO code in the kidney.

Authors:  Zhen Yang; Yuming Zhang; Shiren Sun
Journal:  J Cell Mol Med       Date:  2018-12-01       Impact factor: 5.310

7.  Chemical shift perturbation mapping of the Ubc9-CRMP2 interface identifies a pocket in CRMP2 amenable for allosteric modulation of Nav1.7 channels.

Authors:  Liberty François-Moutal; David Donald Scott; Samantha Perez-Miller; Vijay Gokhale; May Khanna; Rajesh Khanna
Journal:  Channels (Austin)       Date:  2018-08-06       Impact factor: 2.581

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.